AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $33.63.

Several equities analysts have commented on the stock. Wolfe Research initiated coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research report on Monday, March 3rd. Finally, Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after acquiring an additional 143,584 shares during the period. Fairmount Funds Management LLC bought a new position in shares of AnaptysBio during the fourth quarter valued at about $24,050,000. Boxer Capital Management LLC bought a new position in AnaptysBio during the 4th quarter worth approximately $17,212,000. Sanofi bought a new position in shares of AnaptysBio in the fourth quarter worth approximately $10,882,000. Finally, Geode Capital Management LLC increased its position in shares of AnaptysBio by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock valued at $6,444,000 after acquiring an additional 21,196 shares during the period.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB traded up $1.49 during trading on Wednesday, reaching $20.55. 599,640 shares of the stock were exchanged, compared to its average volume of 591,298. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31. The firm has a market cap of $630.21 million, a price-to-earnings ratio of -3.38 and a beta of -0.09. The stock has a fifty day moving average of $17.63 and a two-hundred day moving average of $20.17.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Sell-side analysts forecast that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase plan on Monday, March 24th that allows the company to buyback $75.00 million in outstanding shares. This buyback authorization allows the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.